Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies.

CNS Drugs · 2026 · PMC12988910 · PMID 41703390

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Interim results from this trial have been posted on the company website suggesting potential clinical benefit, but results did not reach statistical significance and at the time of writing analysis is still ongoing.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.